In:
Menopause, Ovid Technologies (Wolters Kluwer Health), Vol. 23, No. 12 ( 2016-12), p. 1303-1306
Abstract:
The aim of this study was to evaluate if levels of gonadotropic and sex steroidal hormones influence the efficacy of mirabegron in the treatment of overactive bladder. Methods: We included 58 female participants who received treatment with mirabegron 50 mg once daily and provided a blood sample for hormone profiling before treatment was initiated. Serum hormone concentrations for estradiol, progesterone, testosterone, FSH, LH, TSH, and T4 were analyzed. Urinary Distress Inventory (UDI), (overactive bladder domain: UDI OAB ), and the short form Pelvic Floor Impact Questionnaire (PFIQ-7) were used to assess subjective outcomes. Results: There were significant overall improvements in UDI, UDI OAB , and the PFIQ from baseline to the 2 months of follow-up ( P = 0.001, 0.001, and 0.008, respectively). The magnitude of the mean difference of improvements was similar between pre- and postmenopausal women. Estrogen levels were nonsignificantly lower in participants who experienced an improvement in UDI and UDI OAB at 2 months of follow-up as compared with those that did not ( P = 0.7). There were no other clinically relevant differences in hormone levels in relation to improvements in UDI, UDI OAB , or PFIQ. In logistic regression analysis there were no associations between UDI OAB outcomes and age, previous use of anticholinergic drugs, parity, menopause, and local estrogen treatment. Conclusions: Estradiol, gonadotropic hormones, thyroid hormones, and testosterone levels did not influence the clinical effects of mirabegron in women with overactive bladder. Menopause status should not be a determinant for mirabegron treatment.
Type of Medium:
Online Resource
ISSN:
1072-3714
,
1530-0374
DOI:
10.1097/GME.0000000000000708
Language:
English
Publisher:
Ovid Technologies (Wolters Kluwer Health)
Publication Date:
2016
detail.hit.zdb_id:
2071114-1
Permalink